Skip to main content
. 2022 May 10;21:111. doi: 10.1186/s12943-022-01549-1

Fig. 3.

Fig. 3

TRAF1 plays a critical role in sunitinib-resistance. A CCK8 assay (450 nm) of sunitinib-sensitive cell lines with and without TRAF1 overexpression under sunitinib treatment (5 μM for 78S, 3 μM for OSS) for 5 days. B CCK8 assay of sunitinib-resistant cell lines with and without TRAF1 knock-down under sunitinib treatment (5 μM for 78R, 3 μM for OSR) for 5 days. C Colony formation assay of sunitinib-sensitive cell lines with and without TRAF1 overexpression under sunitinib treatment (2 μM). D Colony formation assay of sunitinib-resistant cell lines with and without TRAF1 knock-down under sunitinib treatment (2 μM). Representative images (left) and average number of colonies (right) are shown. E EdU assay of sunitinib-sensitive cell lines with and without TRAF1 overexpression under sunitinib treatment (3 μM). F EdU assay of sunitinib-resistant cell lines with and without TRAF1 knock-down under sunitinib treatment (5 μM). G Flow cytometry of sunitinib-sensitive cell lines with and without TRAF1 overexpression under sunitinib treatment (3 μM). H Flow cytometry of sunitinib-resistant cell lines with and without TRAF1 knock-down under sunitinib treatment (5 μM). Stable expression cell lines were used in the above experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001